Systemic Treatments for Alopecia Areata Registry — STA2R  

Autoimmune Diseases Clinical Trial

Official title: Systemic Treatments for Alopecia Areata Registry

Status Recruiting

Clinical Trial Summary

A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.

Clinical Trial Description

Rationale: Alopecia areata (AA) is a dermatological disorder characterized by non-scarring hair loss, significantly affecting the quality of life of patients. While some patients experience spontaneous hair regrowth or respond well to localized treatments, patients with moderate-to-severe AA represent a subgroup that requires more extensive systemic therapies for effective management. Currently, the clinical management of moderate-to-severe AA is primarily based on expert opinions. There is a lack of research on systemic treatments for moderate-to-severe AA, comprising only a small number of randomized controlled trials and observational studies. Furthermore, there is a clear absence of long-term, prospective, and comparative data on these therapies. Most conventional systemic treatments for AA are prescribed off-label, underlining the importance of gaining a more comprehensive understanding of their effectiveness and safety. Therefore, a long-term prospective registry is conducted. This registry will evaluate the real-world utilization of systemic treatments in AA patients, aiming to provide valuable insights into the effectiveness, safety, and long-term outcomes of these therapies. By collecting and analyzing such data, this registry endeavors to contribute to evidence-based clinical management, ultimately improving care for AA patients. Objective: The aim is to establish a comprehensive cohort of AA patients receiving systemic treatments, with the primary objective of assessing the short- and long-term effectiveness and safety of various systemic treatments for AA. Study type: This is a long-term multicenter prospective, observational, non-interventional registry. Study population: All adult AA patients starting systemic treatment, who are willing to provide voluntary informed consent prior to inclusion in the registry and comply with the requirements of the registry. ;

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Alopecia Drugs
• Alopecia Totalis
• Alopecia Universalis
• Autoimmune Diseases
• Hair Loss

• NCT number: NCT06283316
• Study type: Observational [Patient Registry]
• Source: Erasmus Medical Center
• Contact: DirkJan Hijnen, MD, PhD
• Phone: 0031 10 704 01 10
• Email: d.hijnen@erasmusmc.nl
• Status: Recruiting
• Start date: January 17, 2024
• Completion date: December 31, 2099